Aro

Carbon-Negative Aro Homes Announces Launch with $21 Million Series A Fundraise

Retrieved on: 
Thursday, November 3, 2022

Aro Homes , the tech-enabled homebuilding startup that designs and builds carbon-negative, precision-engineered and user experience-optimized homes faster and more cost-effectively than traditional homes, today announced its public launch with $21 million in funding.

Key Points: 
  • Aro Homes , the tech-enabled homebuilding startup that designs and builds carbon-negative, precision-engineered and user experience-optimized homes faster and more cost-effectively than traditional homes, today announced its public launch with $21 million in funding.
  • The way we live has changed, but our homes and the way we build them havent kept up, said Aro Homes Co-CEO Carl Gish.
  • Aro Homes is an early stage company focused on designing and building carbon negative, sustainably built, single-family homes with a new approach to residential construction.
  • Aro Homes has partnered with leading architects, designers and builders to develop more livable, environmentally friendly homes.

Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease

Retrieved on: 
Thursday, September 15, 2022

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug (RPD) designation for ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in muscle, for the treatment of Pompe disease.

Key Points: 
  • Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Drug (RPD) designation for ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in muscle, for the treatment of Pompe disease.
  • Pompe disease is a rare and deadly disease that can manifest at any age of life, including infancy.
  • ABX1100 is a novel approach to treating Pompe disease that aims to reduce glycogen buildup in the muscles.
  • The FDA awards RPD designation to drugs treating rare pediatric diseases that are serious or life-threatening and affect patients from birth to 18 years of age.

INTRODUCING ARO: THE FIRST CONNECTED DEVICE THAT RESULTS IN LESS SCREEN TIME AND MORE REAL LIFE

Retrieved on: 
Wednesday, June 15, 2022

ATLANTA, June 15, 2022 /PRNewswire/ -- Aro Technology, Inc. is proud to introduce Aro: the first connected "smart box" that results in less screen time by helping users put down their phones and experience life uninterrupted. The Aro smart box holds up to four mobile phones, and paired with the Aro app, tracks time spent phone-free. The app measures trends and progress toward goals, helping users stay motivated to unplug by gamifying the experience. The Aro smart box even charges your phone while you recharge away from it.

Key Points: 
  • The Aro smart box holds up to four mobile phones, and paired with the Aro app, tracks time spent phone-free.
  • But for the times when people actually want to put their phones away, it's easier said than done.
  • "Our phones are great, but sometimes they can interrupt us from the real world in front of us," said Wilson.
  • Aro is judgment-free, recognizing the significant value of a mobile phone while also helping people rediscover the world around them.

Keystone Property Group Signs Two More Life Sciences Companies At The Curtis

Retrieved on: 
Wednesday, August 4, 2021

Keystone Property Group announced today it has signed two leases with Aro Biotherapeutics Company and a classified, Penn-incubated biotech company at the landmark publishing house, The Curtis .

Key Points: 
  • Keystone Property Group announced today it has signed two leases with Aro Biotherapeutics Company and a classified, Penn-incubated biotech company at the landmark publishing house, The Curtis .
  • Keystone purchased the 12-floor, 912,245-square-foot building in 2014 and converted former printing press space to wet lab space for life sciences companies like Aro, Vivodyne, and IMVAX.
  • For those interested in joining the life sciences ecosystem at The Curtis, there are currently two INQ lab suites available for lease.
  • The decisions of these best-in-class companies further illustrate the strategic imperative of The Curtis, says Keystone Founder and CEO Bill Glazer.

Amarillo announces succession plan for country manager

Retrieved on: 
Thursday, July 15, 2021

Mr. Serpa, an accomplished mining engineer from Brazil, will succeed Aro Portugal as Country Manager for Amarillos Brazilian subsidiaries when Mr. Portugal retires at the end of September.

Key Points: 
  • Mr. Serpa, an accomplished mining engineer from Brazil, will succeed Aro Portugal as Country Manager for Amarillos Brazilian subsidiaries when Mr. Portugal retires at the end of September.
  • His previous experience includes three years at Yamana Gold, where as Country Manager for Honduras, he led the expansion of its San Andres mine and the Mercedes Mine in Mexico.
  • On behalf of the Board of Directors and the entire Amarillo team, Id like to thank Arao for his leadership, said Mutchler.
  • Amarillo trades on the TSXV under the symbol AGC and the OTCQB under the symbol AGCBF.

Arrowhead Earns $10 Million Option Exercise Fee

Retrieved on: 
Tuesday, May 18, 2021

Receipt of the option notice earns Arrowhead a $10 million option exercise fee and grants Janssen all rights, including licenses, and obligations to develop and commercialize ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead\xe2\x80\x99s proprietary Targeted RNAi Molecule (TRiM\xe2\x84\xa2) platform.\nChris Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: \xe2\x80\x9cThe collaboration with Janssen, which was executed in 2018, for ARO-HBV against chronic hepatitis B infection, and potentially three additional programs, has been highly productive and collaborative.

Key Points: 
  • Receipt of the option notice earns Arrowhead a $10 million option exercise fee and grants Janssen all rights, including licenses, and obligations to develop and commercialize ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead\xe2\x80\x99s proprietary Targeted RNAi Molecule (TRiM\xe2\x84\xa2) platform.\nChris Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: \xe2\x80\x9cThe collaboration with Janssen, which was executed in 2018, for ARO-HBV against chronic hepatitis B infection, and potentially three additional programs, has been highly productive and collaborative.
  • We are thrilled that Janssen has decided to exercise its option on ARO-JNJ1 and move forward with clinical studies.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.\n'

ARO Announces Partnership with Changepoint-based PMO Solution

Retrieved on: 
Tuesday, March 23, 2021

Through a multi-year, hands on, due diligence process of using various technologies to manage portfolios & projects, ARO is excited to announce its partnership with Changepoint (now a part of Planview) to offer a PMO solution comprised of ARO's deep project management expertise using leading Changepoint products.

Key Points: 
  • Through a multi-year, hands on, due diligence process of using various technologies to manage portfolios & projects, ARO is excited to announce its partnership with Changepoint (now a part of Planview) to offer a PMO solution comprised of ARO's deep project management expertise using leading Changepoint products.
  • ARO's deep PMO and project management expertise partnered with Changepoint's leading solutions, will simplify an organization's entire portfolio of projects."
  • ARO is confident that the combination of expertise with Changepoint's leading technology solution will exceed the expectations of clients.
  • ARO will leverage the Changepoint solution in several ways, for virtual PMO implementations; to execute project management; and to provide training and guidance within client environments to empowertheir project team members.

SAFFRON TECH POISED TO ACCELERATE PROOF OF CONCEPT PROCESS WITH VOLCANI CENTER

Retrieved on: 
Tuesday, March 9, 2021

Saffron Tech hopes to disrupt the billion-dollar saffron market with its innovative indoor vertical growing technology that offers an alternative to traditional farming methods that are labor-intensive.

Key Points: 
  • Saffron Tech hopes to disrupt the billion-dollar saffron market with its innovative indoor vertical growing technology that offers an alternative to traditional farming methods that are labor-intensive.
  • Entering this agreement is a major milestone for Saffron Tech who is looking to produce a reliable source of saffron for mass operations.
  • Entering this agreement with ARO, Volcani Center puts Saffron Tech in a strong position for fast growth and ultimately bringing our vertical growing technology to market, says David Freidenberg, CEO, Seedo Corp and Saffron Tech.
  • ARO Volcani Center is Israels largest and most prestigious agricultural research center.

Aro Biotherapeutics Expands Leadership Team with Addition of Proven Scientific Executives

Retrieved on: 
Tuesday, February 23, 2021

The addition of top talent with deep functional experience is a critical success driver for Aro as we enter our next phase of growth, stated Sue Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics.

Key Points: 
  • The addition of top talent with deep functional experience is a critical success driver for Aro as we enter our next phase of growth, stated Sue Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics.
  • Adam Dinerman, Ph.D., brings over twenty years of experience in pharmaceutical development, technology transfer, and manufacturing to Aro Biotherapeutics.
  • Over the course of his career, John has led teams that have successfully progressed multiple drug candidates into clinical development.
  • Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Retrieved on: 
Friday, February 19, 2021

This includes a poster on the preclinical evidence of its lead asset, SENS-401, supporting the therapeutic protocol used in the companys clinical trial on sudden sensorineural hearing loss (SSNHL).

Key Points: 
  • This includes a poster on the preclinical evidence of its lead asset, SENS-401, supporting the therapeutic protocol used in the companys clinical trial on sudden sensorineural hearing loss (SSNHL).
  • The poster on SENS-401 is one of three Sensorion presentations to be featured at the ARO MidWinter Meeting, which will take place on February 20-24, 2021.
  • The Association for Research in Otolaryngology (ARO) is the worlds largest organization of hearing and balance researchers both basic and clinical.
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion.